TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

Patterns of Th1/Th2 Cytokines Predict Clinical Response in Multiple Sclerosis Patients Treated with Glatiramer Acetate

(2011) Hayrettin Tumani et al.   EUROPEAN NEUROLOGY

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism

(2011) Jaime Ramos-Cejudo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

(2009) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

(2009) J. Mellergård et al.   Multiple Sclerosis Journal

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells

(2009) P. Kivisakk et al.   NEUROLOGY

Natalizumab: Bound to rebound?

(2009) N. Schiess et al.   NEUROLOGY

Induction of systemic TNFα in Natalizumab-treated multiple sclerosis

(2008) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Therapeutic targeting of chemokine signaling in Multiple Sclerosis

(2008) Isabell Hamann et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-β treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression

(2008) M Krakauer et al.   Multiple Sclerosis Journal

Effect of interferon-β and atorvastatin on Th1/Th2 cytokines in multiple sclerosis

(2008) Johann Sellner et al.   NEUROCHEMISTRY INTERNATIONAL